RxDoctor Payments Data

Nolan Riley

Optometrist · Lubbock, TXNPI 1366459687

Payments from drug & device makers

$2,934in general payments, 2019–2025

Across 75 payments — averaging $39.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$960
  • Alcon$722
  • Biotissue Holdings Inc.$431
  • Johnson & Johnson Vision Care, Inc.$144
  • ABB Con-cise Optical Group LLC$134
  • AbbVie$102
  • plus $441 from 11 others

What the payments were for

  • Speaking & faculty fees$75026%
  • Food & beverage$2,18474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,934 in reported general payments places this provider in the 80th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$57,192
Medicare patients
326
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost116$57,238
MieboPerfluorohexyloctane/Pf20$14,804
VyzultaLatanoprostene Bunod27$11,135
XiidraLifitegrast12$9,281
RhopressaNetarsudil Mesylate13$4,677
Travoprost28$4,543
SimbrinzaBrinzolamide/Brimonidine Tart15$3,350
Lotemax SmLoteprednol Etabonate13$3,173
Latanoprost131$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$102$57,238116 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra$41$35,22159 claims
AlconSimbrinza$722$3,35015 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$34$3,17313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →